Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Placebo-controlled Study of AMG 181 in Moderate to Severe Crohn's Disease
2012-000529-31Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AMG 181 with Placebo (2 arms). Primary endpoint: CDAI remission at week 8. Started Sep 2012; status: completed.
02
Drugs
abrilumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2012-000529-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000529-31.